Informations:
Erreur:
ID
12248
Description
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). NCT00090051 BO17072
Mots-clés
Versions (2)
- 01/10/2015 01/10/2015 -
- 28/10/2015 28/10/2015 -
Téléchargé le
28 octobre 2015
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
CLL Follow-Up BO17072 NCT00090051
Follow-Up Study completion Chronic Lymphocytic Leukemia BO17072 NCT00090051
Similar models
Follow-Up Study completion Chronic Lymphocytic Leukemia BO17072 NCT00090051
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Info
Item
Info
text
Date of 1st confirmation
Item
Date of 1st confirmation
date
C1611825 (UMLS CUI [1])
Remarks of 1st confirmation
Item
Remarks of 1st confirmation
text
C0282411 (UMLS CUI [1])
Date of 2nd Confirmation
Item
Date of 2nd Confirmation
date
C0750484 (UMLS CUI [1])
Remarks of 2nd confirmation
Item
Remarks of 2nd confirmation
text
C0282411 (UMLS CUI [1])
Date of 1st confimation
Item
Date of 1st confirmation
date
C1611825 (UMLS CUI [1])
Remarks of 1st confirmation
Item
Remarks of 1st confirmation
text
C0282411 (UMLS CUI [1])
Date of 2nd confirmation
Item
Date of 2nd confirmation
date
C0750484 (UMLS CUI [1])
Remarks of 2nd confirmation
Item
Remarks of 2nd confirmation
text
C0282411 (UMLS CUI [1])
Completion
Item
Did the patient complete the study up to the end of 5 year follow-up?
boolean
Date of last contact
Item
Date of last contact
date
C0805839 (UMLS CUI [1])
Study completion
Item
Did the patient complete the study up to the end of the treatment phase?
boolean
C3274569 (UMLS CUI [1])
CL Item
adverse event/intercurrent illness (1)
C0877248 (UMLS CUI-1)
CL Item
death (complete death page) (2)
C0011065 (UMLS CUI-1)
CL Item
insufficient therapeutic response (3)
C0521982 (UMLS CUI-1)
CL Item
failure to return (4)
C0332156 (UMLS CUI-1)
CL Item
did not cooperate/withdrew consent (5)
C0586888 (UMLS CUI-1)
CL Item
administrative/other (6)
C1320722 (UMLS CUI-1)
Specify violation of selection criteria
Item
Specify violation of selection criteria
text
C0242801 (UMLS CUI [1])
Specify other protocol violation
Item
Specify other protocol violation
text
C1709750 (UMLS CUI [1])
Specify other reason
Item
Specify other reason
text
C3840932 (UMLS CUI [1])
Date of contact
Item
Date of contact
date
C0805839 (UMLS CUI [1])
CL Item
alive (1)
C2584946 (UMLS CUI-1)
CL Item
death (2)
C0011065 (UMLS CUI-1)
CL Item
lost to follow-up (3)
C1302313 (UMLS CUI-1)
Date of Death
Item
Date of death
date
C1148348 (UMLS CUI [1])
Date of last contact
Item
Date last contact
date
C0805839 (UMLS CUI [1])
CL Item
progressive disease (1)
C1335499 (UMLS CUI-1)
CL Item
other (2)
C0205394 (UMLS CUI-1)
CL Item
not known (3)
C0439673 (UMLS CUI-1)
Specify other cause of death
Item
Specify other cause of death
text
C0007465 (UMLS CUI [1])
Item
Did the patient’s disease progress after coming off study?
integer
C0242656 (UMLS CUI [1])
CL Item
yes (1)
C1705108 (UMLS CUI-1)
CL Item
no (2)
C1298908 (UMLS CUI-1)
CL Item
not known (3)
C0439673 (UMLS CUI-1)
CL Item
not applicable (progressive disease already documented) (4)
C1272460 (UMLS CUI-1)
Date of progressive disease
Item
Date of progressive disease
date
C0011008 (UMLS CUI [1])